Signal transducer and activator of transcription-3 and breast cancer prognosis.

Signal transducer and activator of transcription-3 (Stat3) is frequently activated in breast cancer and multiple lines of evidence suggest that Stat3 promotes tumor progression. However, the prognostic value of Stat3 in human breast cancer remains controversial and associations range from favorable to unfavorable based on four outcome studies of 62, 102, 255 and 517 patients. Cellular Stat3 protein expression was measured in three studies whereas nuclear localized, tyrosine phosphorylated Stat3 (Nuc-pYStat3) was used as the readout in only one study. We therefore retrospectively analyzed the prognostic value of Nuc-pYStat3 in a larger material of 721 breast cancer specimens. Overall, patients whose tumors were positive for Nuc-pYStat3 tended to have improved survival, but the trend did not reach statistical significance (P=0.08). When specimens were stratified by tumor grade, patients with low grade but not high grade tumors that were positive for Nuc-pYStat3 had significantly prolonged overall survival in univariate analysis (P=0.014) but not in multivariate analyses. Unexpectedly, quantitative immunofluoresence detection revealed highest levels of Nuc-pYStat3 in normal breast epithelia and gradual loss of Nuc-pYStat3 during progression from DCIS, invasive ductal carcinoma, and lymph node metastases. Levels of Nuc-pYStat3 correlated positively with levels of Nuc-pYStat5, a favorable prognostic marker, in invasive ductal carcinomas. Furthermore, NucpYStat3 levels correlated strongly with protein levels of nuclear localized Stat5a (r=0.633, P<0.001) but not Stat5b. Our data does not support the notion that Nuc-pYStat3 is an independent marker of prognosis in breast cancer, although future studies may reveal prognostic utility within molecularly characterized subtypes of breast cancer.

[1]  G. A. Stringer,et al.  Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Pui-Kai Li,et al.  Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. , 2010, Cancer research.

[3]  J. Turkson,et al.  Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. , 2010, Cancer research.

[4]  H. Rui,et al.  Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. , 2010, Cancer research.

[5]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[6]  J. Parsons,et al.  A novel role for signal transducer and activator of transcription 5b (STAT5b) in β1-integrin-mediated human breast cancer cell migration , 2009, Breast Cancer Research.

[7]  A. Richardson,et al.  Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.

[8]  S. Sheen-Chen,et al.  Prognostic Value of Signal Transducers and Activators of Transcription 3 in Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  J. Wen,et al.  Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. , 2008, Molecular endocrinology.

[10]  D. Coppola,et al.  Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function* , 2008, Journal of Biological Chemistry.

[11]  A. Sultan,et al.  Co‐overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial–mesenchymal transition , 2008, Cancer science.

[12]  M. Wasik,et al.  STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression , 2007, Nature Medicine.

[13]  H. Yamashita,et al.  Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. , 2006, Endocrine-related cancer.

[14]  Alan Cantor,et al.  Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression , 2006, Clinical Cancer Research.

[15]  Hallgeir Rui,et al.  Ultrahigh density microarrays of solid samples , 2005, Nature Methods.

[16]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[17]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Sultan,et al.  Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells , 2005, Oncogene.

[19]  J. Xie,et al.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Li Li,et al.  Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.

[22]  E. Dreher,et al.  EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. , 2001, International journal of oncology.

[23]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[24]  Hua Yu,et al.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.

[25]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[26]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[27]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  R. Jove,et al.  Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.

[29]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[30]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[31]  Nancy Reid,et al.  Statistical Theory and Modeling: In Honour of Sir David Cox, FRS. , 1992 .

[32]  L. Kenner,et al.  The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. , 2009, Frontiers in bioscience.

[33]  S. Dewilde,et al.  The STAT3 isoforms alpha and beta have unique and specific functions. , 2004, Nature immunology.